Rezolute (RZLT) Non Operating Income (2012 - 2026)
Rezolute (RZLT) posted Non Operating Income of $1.2 million for Q1 2026, down 17.42% sequentially from $1.4 million in Q4 2025, and up 7.75% YoY from $1.1 million in Q1 2025.
Analysis
Rezolute (RZLT) Non Operating Income (2012 - 2026) Analysis & Trends
Rezolute has reported Non Operating Income for 15 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Non Operating Income rose 7.75% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 39.08% YoY) and the FY2025 annual result came in at $5.5 million, up 179.12% from the prior year.
- Non Operating Income retreated to $1.2 million in Q1 2026 per RZLT's latest filing, from $1.4 million in the prior quarter.
- Over five years, Non Operating Income peaked at $2.1 million in Q2 2022 and troughed at -$837000.0 in Q1 2024.
- A 5-year average of $1.0 million and a median of $1.3 million in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income soared 1346.58% in 2022, then sank 156.94% in 2024.
- Over 5 years, Non Operating Income stood at $836000.0 in 2022, then jumped by 53.71% to $1.3 million in 2023, then climbed by 5.06% to $1.3 million in 2024, then advanced by 7.19% to $1.4 million in 2025, then slipped by 17.42% to $1.2 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.2 million, $1.4 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Rezolute | 475.98 Mn | 475.98 Mn | - | 1.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | -837,000.00 |
| Dec 31, 2023 | 1.29 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.51 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 836,000.00 |
| Sep 30, 2022 | 387,000.00 |
| Jun 30, 2022 | 1.88 Mn |
| Mar 31, 2022 | -454,000.00 |
| Dec 31, 2021 | -444,000.00 |
| Sep 30, 2021 | -196,000.00 |
| Jun 30, 2021 | 146,000.00 |